Mirvetuximab Soravtansine 100mg Injection — Antibody-Drug Conjugate for Folate Receptor Alpha-Positive Ovarian Cancer
Elahere® (Mirvetuximab Soravtansine) — Targeted Therapy for FRα-Positive Ovarian Cancer
A Sourcing Guide for Hospitals Treating Platinum-Resistant Ovarian Cancer
Elahere® (Mirvetuximab Soravtansine) is an antibody-drug conjugate (ADC) indicated, according to its approved prescribing information, for adults with folate receptor alpha-positive (FRα+) ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have not responded to or are no longer responding to platinum-based chemotherapy, and who have received 1 to 3 prior lines of chemotherapy. As with all oncology biologics, the decision to prescribe Elahere, including patient selection based on FRα testing, rests entirely with the treating oncologist, in accordance with the approved label. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Elahere (Mirvetuximab Soravtansine) 100mg to hospitals, oncology centres, and pharmacies across India, with cold chain-compliant handling throughout procurement and delivery.
Elahere is an antibody-drug conjugate — a class of oncology medicine that combines a monoclonal antibody with a cytotoxic payload, designed to deliver treatment directly to cancer cells expressing a specific target.
Folate Receptor Alpha and Its Role in Ovarian Cancer:
According to the manufacturer’s prescribing information, Elahere’s antibody component targets folate receptor alpha (FRα), a protein frequently overexpressed on the surface of epithelial ovarian cancer cells relative to normal tissue. This targeted mechanism is why FRα testing using an approved companion diagnostic is required before treatment, ensuring the medicine is used only in patients whose tumours express the target it is designed to reach.
How the ADC Delivers Its Effect: Once the antibody component binds FRα on the tumour cell surface, the antibody-drug complex is internalised into the cell. Inside the cell, the linker connecting the antibody to its cytotoxic payload (DM4, a maytansinoid microtubule inhibitor) is cleaved, releasing the cytotoxic agent directly within the cancer cell. This mechanism is designed to concentrate cytotoxic activity specifically at FRα-expressing tumour cells, according to the manufacturer’s published pharmacology data, distinguishing it from conventional chemotherapy that circulates and acts more broadly throughout the body.
Full prescribing information is available at the FDA label for Mirvetuximab Soravtansine, with additional background on ovarian cancer biology available via the National Cancer Institute.
SORAYA Trial (Mirvetuximab Soravtansine in Platinum-Resistant, FRα-High Ovarian Cancer)
Published in the Journal of Clinical Oncology (2023), the pivotal SORAYA trial evaluated Elahere in patients with platinum-resistant, high-grade serous ovarian cancer with high FRα expression, who had received 1 to 3 prior lines of therapy including bevacizumab. Key findings included a clinically meaningful overall response rate in this heavily pretreated population, supporting its accelerated approval in this setting.
MIRASOL Trial (Confirmatory Phase 3 Trial)
Published in the New England Journal of Medicine (2023), the confirmatory MIRASOL trial compared Elahere against investigator’s choice chemotherapy in patients with FRα-high, platinum-resistant ovarian cancer. Key results demonstrated significantly improved progression-free survival and overall survival with Elahere compared to chemotherapy, along with a more favourable side effect profile in several respects, providing the confirmatory evidence supporting full regulatory approval.
For broader clinical guidance on ovarian cancer management, the Society of Gynecologic Oncology publishes ongoing treatment guidelines.
Elahere is available as:
| Presentation | Strength |
|---|---|
| Elahere 100mg Injection | 100mg per vial |
Dosing is calculated based on body weight (mg/kg) by the prescribing oncologist, in accordance with the approved prescribing information.
Folate Receptor Alpha-Positive Ovarian Cancer:
FRα biomarker testing using an approved companion diagnostic test is required before initiating Elahere therapy, per the approved prescribing information.
For detailed indication information refer to MedlinePlus Ovarian Cancer.
First Approved ADC for This Specific Ovarian Cancer Population
Elahere represented a new targeted treatment mechanism for platinum-resistant, FRα-positive ovarian cancer, a population with historically limited effective treatment options.
Confirmed Survival Benefit in Phase 3 Trial
The MIRASOL trial demonstrated statistically significant improvement in both progression-free and overall survival compared to standard chemotherapy, providing confirmatory Phase 3 evidence supporting its clinical benefit.
Targeted Mechanism With Distinct Side Effect Profile
As an antibody-drug conjugate targeting FRα specifically, Elahere’s mechanism is designed to concentrate cytotoxic activity at the tumour site, with a side effect profile studied and compared against conventional chemotherapy in the MIRASOL trial.
Biomarker-Directed Precision Approach
By requiring FRα testing before treatment, Elahere represents a precision oncology approach, directing therapy specifically toward tumours confirmed to express the target.
Dosing of Elahere is determined by the prescribing oncologist according to the approved label. General administration information from the manufacturer’s prescribing information includes:
Monitoring (per manufacturer prescribing information):
Full dosing guidelines are available in the manufacturer’s official prescribing information and should always be followed exactly as directed by the treating oncologist.
Elahere is prescribed by gynaecologic oncologists for:
Elahere is prescribed by oncologists specialising in gynaecologic malignancies. A.K. Pharma supplies Elahere to hospitals and oncology centres across Delhi and India.
Common side effects reported in clinical trials include blurred vision, keratopathy, nausea, fatigue, peripheral neuropathy, and abdominal pain.
Serious side effects include:
Ocular Toxicity, Including Keratopathy: A Boxed Warning addresses the risk of ocular adverse events, including keratopathy, which can affect vision. Regular ophthalmologic examinations, including visual acuity assessment prior to each dose, are required per the approved prescribing information, with dose modification guidance provided based on findings.
Peripheral Neuropathy: Reported as a common adverse event, consistent with the cytotoxic payload class used in this ADC; monitoring and management guidance per the approved label.
Interstitial Lung Disease/Pneumonitis: Pulmonary adverse events have been reported; prompt evaluation of new or worsening respiratory symptoms is recommended per the approved label.
Infusion-Related Reactions: Reported with intravenous administration; monitoring during and after infusion is recommended per standard oncology infusion protocols.
Full side effect information is available at FDA Mirvetuximab Soravtansine Safety Information.
As a responsible medicine distributor in Delhi, A.K. Pharma stores all oncology biologics including Elahere under manufacturer-recommended cold chain conditions ensuring product integrity for every supply.
Elahere (Mirvetuximab Soravtansine) is manufactured by ImmunoGen (now part of AbbVie). It received accelerated approval based on the SORAYA trial, with subsequent full approval supported by confirmatory Phase 3 data from the MIRASOL trial. A.K. Pharma supplies only genuine Elahere sourced from authorised distributors.
Q. What is Elahere used for?
Elahere (Mirvetuximab Soravtansine) is used to treat adults with folate receptor alpha-positive (FRα+), platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of chemotherapy.
Q. What is the generic name of Elahere?
The generic name of Elahere is Mirvetuximab Soravtansine, an antibody-drug conjugate targeting folate receptor alpha.
Q. Why is FRα testing required before starting Elahere?
Elahere is approved specifically for tumours expressing folate receptor alpha at a level confirmed by an approved companion diagnostic test, since the medicine’s targeting mechanism depends on this receptor being present on the tumour surface.
Q. Why does Elahere require regular eye examinations during treatment?
Elahere carries a Boxed Warning for ocular toxicity, including keratopathy, which is why visual acuity assessment and ophthalmologic examination are required before each dose, per the approved prescribing information.
Q. Is Elahere available in India?
Elahere can be supplied to hospitals and oncology centres across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi and pharmaceutical distributor in Delhi — for availability and pricing.
Q. What is the price of Elahere in India?
Elahere price in India varies by order quantity. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Elahere from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Elahere in bulk?
Yes. A.K. Pharma supplies Elahere in bulk to hospitals and oncology centres across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
